Daiwa Securities Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Daiwa Securities Group’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2	Closed	–	–	1411
2023 Q3	$0	Hold	2	–	–	﹤0.01%	1350
2023 Q2	$0	Hold	2	–	–	﹤0.01%	1366
2023 Q1	$0	Hold	2	–	–	﹤0.01%	1331
2022 Q4	$0	Hold	2	–	–	﹤0.01%	1410
2022 Q3	$1K	Hold	2	–	–	﹤0.01%	1325
2022 Q2	$0	Hold	2	–	–	﹤0.01%	1450
2022 Q1	$1K	Hold	2	–	–	﹤0.01%	1358
2021 Q4	$0	Hold	2	–	–	﹤0.01%	1464
2021 Q3	$0	Hold	2	–	–	﹤0.01%	1350
2021 Q2	$1K	Hold	2	–	–	﹤0.01%	1231
2021 Q1	$1K	Hold	2	–	–	﹤0.01%	1242
2020 Q4	$1K	Sell	2 -2	-50%	-$574	﹤0.01%	1224
2020 Q3	$1K	Hold	4	–	–	﹤0.01%	1172
2020 Q2	$1K	Hold	4	–	–	﹤0.01%	1198
2020 Q1	$1K	Hold	4	–	–	﹤0.01%	1201
2019 Q4	$2K	Hold	4	–	–	﹤0.01%	1174
2019 Q3	$1K	Hold	4	–	–	﹤0.01%	1164
2019 Q2	$1K	Hold	4	–	–	﹤0.01%	1189
2019 Q1	$2K	Buy	+4	New	+$1.6K	﹤0.01%	1145

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Daiwa Securities Group's EIGR Position: Q4 2023 in Review

Daiwa Securities Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 2 shares.

Daiwa Securities Group first reported a position in EIGR in Q1 2019 and held it in 19 quarters. The position peaked at $2K in Q4 2019. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

Daiwa Securities Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Daiwa Securities Group sold 2 Eiger BioPharmaceuticals, Inc. shares in Q4 2023.
Daiwa Securities Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2019 and held it in 19 quarters.
Daiwa Securities Group's Eiger BioPharmaceuticals, Inc. position peaked at $2K in Q4 2019.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.